Abpro Holdings, Inc. (ABPWW) Aktienanalyse

Abpro Holdings, Inc., a biotechnology company, focuses on the development of novel antibodies using discovery and engineering platforms for immuno-oncology, ophthalmology, and infectious disease in the United States. Its platforms include DiversImmune, an antibody discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides flexibility to combine antibody building blocks in different combinations and orientations to create fit-for-purpose novel full-length multispecific antibody constructs. The company's lead product candidates include ABP-102, a next-generation immuno-oncology TetraBi antibody targeting HER2 and CD3 developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibits VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnerships with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.

Die Unternehmensbeschreibung wird auf Englisch angezeigt.